Table 2 Serum and urinary biochemical parameters of patients with chronic hepatitis B virus infection in use or not of antiretrovirals.

From: Bone loss in hepatitis B virus-infected patients can be associated with greater osteoclastic activity independently of the retroviral use

Variables

Group 1

Without antiretrovirals

Group 2

Tenofovir

Group 3

Lamivudine/Entecavir

p value

Reference values

n

27

27

27

  

DPD (nmol/mmol)

8.09 ± 2.98

9.23 ± 2.4

8.29 ± 2.5

0.295

2.3–7.4

Osteocalcin (ng/ml)

7.3 ± 3.95a

10.6 ± 5.67b

7.50 ± 3.85ab

0.025

< 2–21

PTH (pg/ml)

35.1 ± 16.0ab

43.2 ± 25.0b

28.0 ± 9.5a

0.011

10–65

IGF-1 (ng/ml)

191.5 ± 115.4

145.1 ± 69.2

137.1 ± 91.9

0.236

101–267

FGF-23 (pg/ml)

62.2 ± 24.7

54 ± 14.1

49.1 ± 19.2

0.168

23.2–95.4

25 OH vitamin D (ng/ml)

27.1 ± 7.1a

32.8 ± 9.2b

32.8 ± 7.9b

0.015

> 20

Total calcium (mg/dl)

9.23 ± 0.48

9.08 ± 0.42

9.17 ± 0.33

0.539

8.8–11

Phosphorus (mg/dl)

3.97 ± 0.64

3.66 ± 0.52

3.64 ± 0.61

0.086

3–7

Magnesium (mg/dl)

2.19 ± 0.18

2.21 ± 0.19

2.23 ± 0.18

0.686

1.9–2.5

Urinary phosphorus (mg/l)

538,6 ± 317,9

652,6 ± 349,2

487,9 ± 273,7

0.133

400–1300

GOT (U/l)

24.5 ± 10.3

24.0 ± 6.14

24.4 ± 9.2

0.982

5–40

GPT (U/l)

28.2 ± 18.4

27.7 ± 16.0

30.1 ± 20.1

0.876

7–56

Creatinine (mg/dl)

0.87 ± 0.1

0.90 ± 0.2

0.96 ± 0.2

0.375

0.6–1.2

Urea (mg/dl)

27.8 ± 7.9

28.6 ± 6.9

30.5 ± 8.0

0.413

10–40

Albumin (g/dl)

4.3 ± 0.5

4.3 ± 0.3

4.5 ± 0.3

0.099

3.5–4.7

  1. ANOVA one way. Values are expressed as mean ± standard deviation. Different letters p ≤ 0.05. DPD, deoxypyridinoline; PTH, parathormone; IGF-1, insulin-like growth factor-1; FGF-23, fibroblast growth factor 23; GOT, glutamic-oxaloacetic transaminase; GPT, glutamic-pyruvic transaminase. FGF-23 n = 16–17 per group.
Back to article page